{"id":982,"date":"2025-10-13T09:59:16","date_gmt":"2025-10-13T09:59:16","guid":{"rendered":"https:\/\/ardenneiratherm.com\/clinical-trials-whole-body-hyperthermia-wira\/"},"modified":"2025-12-22T09:24:42","modified_gmt":"2025-12-22T09:24:42","slug":"klinikiniai-tyrimai-hipertermija-onkologija","status":"publish","type":"page","link":"https:\/\/ardenneiratherm.com\/lt\/klinikiniai-tyrimai-hipertermija-onkologija\/","title":{"rendered":"Klinikiniai tyrimai"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"982\" class=\"elementor elementor-982 elementor-756\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ea8f7b2 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"ea8f7b2\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInDown&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f3c7e79 elementor-widget elementor-widget-heading\" data-id=\"f3c7e79\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Viso K\u016bno Hipertermija (VKH \/ WBH) Onkologijoje ir Kitose Patologijose: Konsoliduota Sinergija, Imunomoduliacija ir Klinikiniai \u012erodymai<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c02c88e animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"c02c88e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header><strong>Paskelbta: <time datetime=\"2025-10-13\">2025-10-13<\/time> | Paskutin\u012f Kart\u0105 Per\u017ei\u016br\u0117ta: <time datetime=\"2025-10-13\">2025-10-13<\/time><\/strong><\/header><p>Autoriai<br \/><a href=\"\/?p=139\">Veronica Iatan, MD<\/a>,<br \/><a href=\"\/?p=137\">Cristian Gologan, M.Sc.<\/a><\/p><section><p style=\"font-weight: bold; font-style: italic;\">Viso K\u016bno Hipertermija (VKH \/ WBH) yra sistemin\u0117 onkologin\u0117 strategija, apimanti kontroliuojam\u0105 k\u016bno bazin\u0117s temperat\u016bros k\u0117lim\u0105, da\u017enai naudojant <i>vandeniu filtruoto Infraraudonojo-A (wIRA)<\/i> technologij\u0105. VKH i\u0161 esm\u0117s yra <i>chemo\/radio sensibilizatorius<\/i>, \u017eymiai <i>pagerinantis naviko perfuzij\u0105 ir apr\u016bpinim\u0105 deguonimi<\/i>, siekiant sustiprinti tradicinio gydymo veiksmingum\u0105. Svarbiausia, ji veikia kaip galingas <i>sisteminis imunomoduliatorius<\/i>, mobilizuojantis Kar\u0161\u010dio \u0160oko Baltymus (K\u0160B) ir T-l\u0105steles, sukuriantis esmin\u0119 sinergij\u0105 su pa\u017eangia <i>Imunoterapija (IKI)<\/i> ir suteikiantis <i>dramati\u0161k\u0105, greit\u0105 skausmo mal\u0161inim\u0105 ir gyvenimo kokyb\u0117s pagerinim\u0105<\/i> sergant \u012fvairiais v\u0117\u017eiais ir l\u0117tin\u0117mis patologijomis, tokiomis kaip Fibromialgija.<\/p><\/section><section><i> Medicinos Atsakomyb\u0117s Apribojimas: \u0160is straipsnis skirtas tik informaciniams tikslams ir nepakei\u010dia individualizuotos medicinin\u0117s konsultacijos, diagnoz\u0117s ar gydymo, kur\u012f teikia licencijuotas gydytojas.<\/i><\/section><section><h2>\u00a0<\/h2><\/section><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-805e6aa e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"805e6aa\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-67bd9be elementor-widget elementor-widget-heading\" data-id=\"67bd9be\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">1. Viso K\u016bno Hipertermijos (VKH \/ WBH) ir Terapin\u0117s Technologijos Apibr\u0117\u017eimas<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-67346b0 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"67346b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><p style=\"text-align: left;\"><strong>Viso K\u016bno Hipertermija (VKH)<\/strong>, arba \u201esistemin\u0117 hipertermija\u201c, apibr\u0117\u017eiama kaip kontroliuojamas k\u016bno bazin\u0117s temperat\u016bros padidinimas terapiniais tikslais. Remiantis <strong>nat\u016bralaus kar\u0161\u010diavimo poveikiu esant skirtingoms temperat\u016broms,<\/strong> VKH proced\u016bros skirstomos taip:<\/p><ul style=\"text-align: left;\"><li><strong>Lengvas VKH:<\/strong> &lt; 38.5<strong>\u00b0<\/strong>C<\/li><li><strong>Vidutinis VKH:<\/strong> 38.5<strong>\u00b0<\/strong>C- 40.5 <strong> \u00b0<\/strong>C<\/li><li><strong>Ekstremalus VKH:<\/strong> &gt; 40.5<strong>\u00b0<\/strong>C<\/li><\/ul><p style=\"text-align: left;\">Vis\u0173 pirma, lengva ir vidutin\u0117 VKH <strong>padidina perfuzij\u0105,<\/strong> stimuliuoja med\u017eiag\u0173 apykait\u0105, ma\u017eina raumen\u0173 tonus\u0105 ir <strong>stimuliuoja imunin\u0119 sistem\u0105.<\/strong><\/p><p style=\"text-align: left;\"><strong><a title=\"Detalii tehnice von Ardenne IRATHERM\u00ae 1000M WBH wIRA device\" href=\"\/?page_id=270\">von Ardenne IRATHERM<\/a><\/strong>\u00ae <strong>1000M VKH wIRA prietaisas<\/strong> \u0161iam tikslui naudoja i\u0161skirtinai <strong>odos suderinam\u0105, giliai \u012f audinius prasiskverbian\u010di\u0105, vandeniu filtruot\u0105 Infraraudonojo-A (wIRA) \u0161ilumos spinduliuot\u0119<\/strong> (be IR-B \/ IR-C). Jo ne-klaustrofobi\u0161ka, atvira sistemos konstrukcija u\u017etikrina vienod\u0105 \u0161vitinimo intensyvum\u0105 visam pacientui (nugaros) lygiui ir si\u016blo naudotojui optimal\u0173, paciento poreikius atitinkant\u012f \u0161ilumos tiekim\u0105 vietos ir intensyvumo at\u017evilgiu.<\/p><p style=\"text-align: left;\">Vandeniu filtruota infraraudon\u0173j\u0173 spinduli\u0173 A spinduliuot\u0117 atitinka nat\u016bral\u0173 Saul\u0117s termin\u012f spinduliavim\u0105, suteikiant technologin\u012f pagrind\u0105 tolygiam ir \u0161velniam \u0161ilumos taikymui [1, 5, 7, 8].<\/p><p style=\"text-align: left;\">Naudojant \u201evon Ardenne IRATHERM<sup>\u00ae<\/sup> 1000\u201c princip\u0105, kuris buvo kuriamas ir \u012frodytas per daugiau nei 30 met\u0173, <a title=\"Prof. Manfred von Ardenne - Contribu\u021bii\" href=\"\/?p=5\">Prof. Manfred von Ardenne<\/a> pavyko fizi\u0161kai ir techni\u0161kai atkartoti \u0161i\u0105 termin\u0119 spinduliuot\u0119 ir pramoniniu b\u016bdu pritaikyti j\u0105 tvariam medicininiam naudojimui per viso k\u016bno hipertermij\u0105<\/p><\/header><\/header><p>\u00a0<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6c924fa elementor-invisible elementor-widget elementor-widget-image\" data-id=\"6c924fa\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/ardenneiratherm.com\/wp-content\/uploads\/2025\/10\/von-Ardenne-Iratherm-10000-WBH-wIRA-hyperthermia-device-wIRA.jpg\" title=\"\" alt=\"von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-wIRA\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-48fd6d3 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"48fd6d3\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-aafa804 elementor-widget elementor-widget-heading\" data-id=\"aafa804\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">2. Moksliniai Pagrindai ir Sisteminiai Poveikiai<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-672df30 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"672df30\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><p style=\"text-align: left;\">VKH i\u0161sivyst\u0117 \u012f strategij\u0105, pagr\u012fst\u0105 tvirtais biofiziniais ir fiziologiniais principais. Onkologijoje d\u0117mesys sutelkiamas \u012f <strong>vidutin\u0119<\/strong> ir <strong>Kar\u0161\u010diavimo Diapazono Hipertermij\u0105 (KD-VKH)<\/strong>, pripa\u017eintas kaip gydymo b\u016bdai, turintys daug terapini\u0173 indikacij\u0173 [1, 3].<\/p><p style=\"text-align: left;\">Technologin\u012f pagrind\u0105 tolygiam ir \u0161velniam \u0161ilumos taikymui da\u017enai u\u017etikrina prietaisai, naudojantys <strong>vandeniu filtruot\u0105 Infraraudonojo-A (wIRA) spinduliuot\u0119<\/strong>. I\u0161sam\u016bs biofizikiniai tyrimai patvirtino \u0161ios <strong>technologijos geb\u0117jim\u0105 u\u017etikrinti gil\u0173 ir kontroliuojam\u0105 \u0161ildym\u0105,<\/strong> atsi\u017evelgiant \u012f odos optines savybes ir fotobiologin\u012f dozavimo pagrind\u0105 [5,7,8].<\/p><p style=\"text-align: left;\">I\u0161sam\u016bs biofizikiniai tyrimai patvirtino <strong>wIRA technologijos<\/strong> geb\u0117jim\u0105 u\u017etikrinti <strong>gil\u0173 ir kontroliuojam\u0105 \u0161ildym\u0105<\/strong> [5, 7, 8]. Fiziologiniu lygmeniu VKH turi esmin\u012f sistemin\u012f poveik\u012f:<\/p><ol style=\"text-align: left;\"><li><strong>Pager\u0117jusi Kraujo Reologija:<\/strong> IR-VKH poveikis teigiamai veikia <strong>kraujo srauto savybes ir hemodinamik\u0105<\/strong> [2], palaikydamas esmin\u012f <strong>naviko perfuzijos pagerinimo<\/strong> mechanizm\u0105 \u2014 kritin\u0119 prielaid\u0105 sisteminio gydymo s\u0117kmei.<\/li><li><strong>Bendras Biologinis Aktyvinimas:<\/strong> VKH sukelia terminio streso atsak\u0105, kuris su\u017eadina biologini\u0173 proces\u0173 kaskad\u0105, \u012fskaitant <strong>hormonin\u0117s sistemos moduliavim\u0105<\/strong> ir <strong>med\u017eiag\u0173 apykaitos pagreitinim\u0105<\/strong> [6, 4].<\/li><\/ol><p style=\"text-align: left;\">D\u0117l \u0161i\u0173 pagrind\u0173 VKH veikia kaip <strong>sisteminis imunomoduliatorius<\/strong>, optimizuojantis <strong>naviko mikroaplink\u0105 (NMA)<\/strong> ir <strong>sustiprinantis pa\u017eangi\u0173 onkologini\u0173 gydymo b\u016bd\u0173 veiksmingum\u0105<\/strong> [9].<\/p><\/header><\/header><h2>\u00a0<\/h2><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-73d38c1 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"73d38c1\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4061817 elementor-widget elementor-widget-heading\" data-id=\"4061817\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">3. Pagrindiniai Veikimo Mechanizmai (Molekuliniai, Fiziologiniai ir Imunologiniai)<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22327e2 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"22327e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><p style=\"text-align: left;\">Terapinis VKH poveikis yra sud\u0117tingas, j\u012f lemia poky\u010diai l\u0105steli\u0173, imunin\u0117s sistemos ir fiziologijos lygmenyse:<\/p><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">\u00a0<\/h3><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5638fef animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"5638fef\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">A. Sinergija su Chemoterapija ir Radioterapija (Chemo\/Radio Sensibilizatorius)<\/h3><ul><li style=\"text-align: left;\"><strong>Naviko Mikroaplinkos (NMA) Optimizavimas:<\/strong> VKH pagerina <strong>naviko kraujo perfuzij\u0105<\/strong> ir <strong>apr\u016bpinim\u0105 deguonimi<\/strong>, panaikindama naviko hipoksij\u0105. Tai yra esminis dalykas, nes gerai apr\u016bpintos deguonimi naviko l\u0105stel\u0117s yra \u017eymiai jautresn\u0117s naikinimui <strong>Chemoterapija<\/strong> (ChT) ir <strong>Radioterapija<\/strong> (RT) [9, 41].<\/li><li style=\"text-align: left;\"><strong>Chemo\/Radio Veiksmingumas:<\/strong> Hipertermija veikia kaip<strong> chemo &amp; radio<\/strong> <strong>sensibilizatorius<\/strong>, pagerindama naviko apr\u016bpinim\u0105 deguonimi (<i> radio-sensibilizuojantis poveikis<\/i> ) ir padidindama vaist\u0173, toki\u0173 kaip Cisplatinas, Gemcitabinas ir Carboplatinas, veiksmingum\u0105 [12, 16, 36].<\/li><\/ul><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">\u00a0<\/h3><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3119e45 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"3119e45\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">B. Tvirto Prie\u0161navikinio Imuninio Atsako Indukcija (Imunomoduliacija)<\/h3><p style=\"text-align: left;\">VKH yra stiprus k\u016bno gynybos sistemos aktyvatorius [11]:<\/p><ul><li style=\"text-align: left;\"><strong>Kar\u0161\u010dio \u0160oko Baltymai (K\u0160B):<\/strong> Terminis stresas skatina <strong>K\u0160B70<\/strong> sintez\u0119 ir i\u0161siskyrim\u0105. \u0160ie baltymai veikia kaip \u201epavojaus signalai\u201c, \u017eymintys v\u0117\u017eio l\u0105steles sustiprintam imunin\u0117s sistemos <strong>Citotoksini\u0173 T Limfocit\u0173 (CTL)<\/strong> puolimui [9, 10, 29].<\/li><li style=\"text-align: left;\"><strong>Pagrindini\u0173 Imunini\u0173 L\u0105steli\u0173 Aktyvinimas:<\/strong> 39-43<strong>\u00b0<\/strong>C temperat\u016bros diapazonas padidina <strong>Nat\u016brali\u0173 \u017dudik\u0173 (NK) l\u0105steli\u0173<\/strong> aktyvum\u0105 ir skatina <strong>pagalbini\u0173 ir citotoksini\u0173 T l\u0105steli\u0173<\/strong>, <strong>dendritini\u0173 l\u0105steli\u0173<\/strong> ir <strong>makrofag\u0173<\/strong> veikl\u0105, tuo pat metu galimai pakenkdamas imunosupresin\u0117ms l\u0105stel\u0117ms [9, 10, 11, 25, 26].<\/li><li style=\"text-align: left;\"><strong>T-Limfocit\u0173 Padid\u0117jimas:<\/strong> KD-VKH gali <strong>\u017eymiai padidinti (pvz., 3 kartus) citotoksini\u0173 T limfocit\u0173 populiacij\u0105<\/strong> limfoidiniuose organuose, taip <strong>sustiprindama sistemin\u012f prie\u0161navikin\u012f imunin\u012f puolim\u0105<\/strong> [10].<\/li><li style=\"text-align: left;\"><strong>Vakcinos ir APC:<\/strong> VKH gali reguliuoti Antigenu Pristatan\u010di\u0173 L\u0105steli\u0173 (APC) funkcij\u0105 ir padidinti v\u0117\u017eio vakcin\u0173, \u012fskaitant tas, kurios pagr\u012fstos K\u0160B110 ir GRP170, veiksmingum\u0105 [37, 28].<\/li><\/ul><\/header><\/header><h2>\u00a0<\/h2><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bbbd880 animated-slow e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"bbbd880\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e99507b elementor-widget elementor-widget-heading\" data-id=\"e99507b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">4. Klinikiniai \u012erodymai ir Sinergija Multimodalin\u0117je Terapijoje<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e6a66ba animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e6a66ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">A. Sinergija su Imunoterapija (Kontrolinio Ta\u0161ko Inhibitoriai &#8211; IKI)<\/h3><p style=\"text-align: left;\">Retrospektyvin\u0117 131 paciento, sergan\u010dio pa\u017eengusiu (IV stadijos) v\u0117\u017eiu, atvejo serija tyr\u0117 multimodalin\u012f protokol\u0105, \u012fskaitant <strong>viso k\u016bno hipertermij\u0105<\/strong> kartu su kontrolinio ta\u0161ko inhibitoriais (Ipilimumabu, Nivolumabu) ir IL-2 [18].<\/p><p style=\"text-align: left;\"><strong>Pagrindin\u0117 I\u0161vada:<\/strong> wIRA Viso K\u016bno Hipertermija buvo nustatyta kaip <strong>neatsiejama ir esmin\u0117 sudedamoji dalis<\/strong>, kuri <strong>maksimaliai padidino prie\u0161navikin\u012f imunin\u012f atsak\u0105<\/strong>.<strong> VKH aktyvuoja ir mobilizuoja T l\u0105steles (indukuojant K\u0160B70 ir i\u0161leid\u017eiant naviko antigenus);<\/strong> kontrolinio ta\u0161ko inhibitoriai tada \u201epa\u0161alina stabd\u012f\u201c i\u0161 \u0161i\u0173 i\u0161 anksto aktyvuot\u0173 T l\u0105steli\u0173, tod\u0117l pa\u017eengusios ligos atveju pasiekiamas ne\u012fprastai didelis palanki\u0173 klinikini\u0173 atsako rodiklis [18].<\/p><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">\u00a0<\/h3><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-464662f animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"464662f\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">B. Klinikin\u0117s Pritaikymo Sritys Sergant \u012evairiais V\u0117\u017eiais<\/h3><ul><li style=\"text-align: left;\"><strong>Kasos V\u0117\u017eys:<\/strong> I-II faz\u0117s protokolai, naudojant lengv\u0105 VKH (KD-VKH) kartu su chemoterapija ir Interferonu-alfa, parod\u0117 <strong>ma\u017eiausiai 50% naviko regresij\u0105 beveik pusei terapijai atspari\u0173 pacient\u0173<\/strong> [4, 22].<\/li><li style=\"text-align: left;\"><strong>Kr\u016bties V\u0117\u017eys (Recidyvas):<\/strong> VKH kartu su pakartotiniu \u0161vitinimu arba radioterapija parod\u0117 veiksmingum\u0105 gydant lokaliai pa\u017eengus\u012f kr\u016bties v\u0117\u017e\u012f ir kr\u016btin\u0117s sienel\u0117s recidyv\u0105, patvirtint\u0105 atsitiktini\u0173 im\u010di\u0173 duomenimis [39, 40].<\/li><li style=\"text-align: left;\"><strong>Kiau\u0161id\u017ei\u0173 V\u0117\u017eys:<\/strong> VKH kartu su <strong>karboplatinu<\/strong> buvo tiriamas II faz\u0117s tyrime pasikartojan\u010dio kiau\u0161id\u017ei\u0173 v\u0117\u017eio atveju [16, 20].<\/li><li style=\"text-align: left;\"><strong>Storoji \u017darna V\u0117\u017eys:<\/strong> VKH wIRA buvo naudojama \u201eVon Ardenne\u201c Sistemini\u0173 V\u0117\u017eio Daugiapakop\u0117s Terapijos (sCDT) kontekste kartu su chemoterapija I\/II faz\u0117s tyrime [15].<\/li><\/ul><\/header><\/header><h2>\u00a0<\/h2><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4cb34f6 e-con-full animated-slow e-flex elementor-invisible e-con e-child\" data-id=\"4cb34f6\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c7ca566 elementor-widget elementor-widget-heading\" data-id=\"c7ca566\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">5. Greitas Skausmo Mal\u0161inimas ir \u017dymus Gyvenimo Kokyb\u0117s (GK) Pagerinimas<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8ec3c40 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"8ec3c40\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><p style=\"text-align: left;\">Pacientai gali patirti greit\u0105 skausmo mal\u0161inim\u0105 ir bendr\u0105 gerov\u0117s pager\u0117jim\u0105, kaip pasteb\u0117ta daktaro Bull\u2019o tyrime [12] ir ypa\u010d naujesniame III faz\u0117s klinikiniame tyrime, atliktame Sahinbas ir kt. [14].<\/p><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">\u00a0<\/h3><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cfebbf0 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"cfebbf0\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">III Faz\u0117s Klinikinis Tyrimas (2024) d\u0117l Kaul\u0173 Metastazi\u0173<\/h3><section>2024 metais Sahinbas ir kolegos paskelb\u0117 III faz\u0117s tyrim\u0105 d\u0117l kaul\u0173 metastazi\u0173 skausmo, daugiausia sergant kr\u016bties ir prostatos v\u0117\u017eiu, naudodami VKH wIRA Iratherm hipertermijos prietaisus kartu su RT [14]. Remiantis \u0161iuo tyrimu, RT tik grup\u0117 patyr\u0117 intensyviausi\u0105 skausm\u0105. Tyrimas buvo baigtas \u012ftraukus 61 pacient\u0105, pra\u0117jus 5 metams nuo pirmojo \u012ftraukimo (2016 m. balandis \u2013 2021 m. vasaris). Galiausiai, Visi\u0161ko Atsako (VA) rodiklis RT + VKH grup\u0117je parod\u0117 did\u017eiausi\u0105 skirtum\u0105, palyginti su RT tik grupe: <strong>47,4% vs. 5,3% atitinkamai per 2 m\u0117nesius po gydymo<\/strong> (P vert\u0117 &lt; 0.05). <strong>Visi\u0161ko skausmo mal\u0161inimo laikas RT + VKH grup\u0117je buvo 10 dien\u0173, o RT tik grup\u0117je \u0161is galutinis ta\u0161kas nebuvo pasiektas.<\/strong> Skausmo progresavimas arba ligos stabilumas buvo pasteb\u0117tas pusei pacient\u0173 RT grup\u0117je per 4 savaites po gydymo. Ta\u010diau <strong>\u0161is balas buvo artimas nuliui RT + VKH pacientams per du m\u0117nesius po gydymo<\/strong>.<strong>I\u0161vados: <\/strong> VKH plius RT parod\u0117 \u017eym\u0173 skausmo mal\u0161inimo padid\u0117jim\u0105 ir trumpesn\u012f atsako laik\u0105, palyginti su RT tik grupe, pacientams, turintiems metastazini\u0173 kaul\u0173 pa\u017eeidim\u0173.<\/section><table border=\"1\"><thead><tr><th>GK Indikatorius\/Skausmo Pager\u0117jimas<\/th><th>RT monoterapija<\/th><th>RT + Hipertermija (VKH wIRA)<\/th><th>Poveikis GK<\/th><\/tr><\/thead><tbody><tr><td><strong>Visi\u0161ko Atsako Rodiklis (VA) po 2 m\u0117nesi\u0173<\/strong> (nulinis skausmo balas)<\/td><td>5,3 %<\/td><td>47,4 %<\/td><td>* <strong>894% padid\u0117jimas<\/strong> * bendros skausmo eliminacijos tikimyb\u0117s.<\/td><\/tr><tr><td><strong>Visi\u0161ko skausmo mal\u0161inimo laikas<\/strong><\/td><td>nebuvo pasiektas<\/td><td>10 dien\u0173<\/td><td><strong>\u201d \u017eymi ir greita\u201d<\/strong> nauda<\/td><\/tr><tr><td style=\"text-align: left;\"><strong>Skausmo Mal\u0161inimo Trukm\u0117 <\/strong><\/td><td style=\"text-align: left;\">Mediana: 28 dienos\/4 savait\u0117s pusei pacient\u0173<\/td><td style=\"text-align: left;\">Mediana: Ne\u012ftraukta per 24 savaites<\/td><td style=\"text-align: left;\">Mal\u0161inimo trukm\u0117 * <strong>padid\u0117ja \u0161e\u0161is kartus<\/strong> *, ma\u017einant priklausomyb\u0119 nuo skausmo mal\u0161intoj\u0173.<\/td><\/tr><\/tbody><\/table><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><p style=\"text-align: left;\">\u00a0<\/p><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e97cd55 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e97cd55\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">Palyginti su pana\u0161iu <a title=\"Phase III Chi MS et al. 2017 Study\" href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\">III faz\u0117s tyrimu, paskelbtu Chi MS et al<\/a> . (2017) su RF lokoregionine hipertermija, nauda (<i>GK ir skausmo suma\u017einimo at\u017evilgiu)<\/i>, pasiekta naudojant VKH wIRA hipertermij\u0105, buvo daug prana\u0161esn\u0117 \u2013 RF HT + RT tyrimo rezultatai\u00a0 :<\/p><table border=\"1\"><thead><tr><th>GK Indikatorius\/Skausmo Pager\u0117jimas<\/th><th>RT monoterapija<\/th><th>RT + Hipertermija (HT)<\/th><th>Poveikis GK<\/th><\/tr><\/thead><tbody><tr><td><strong>Visi\u0161ko Atsako Rodiklis (VA) po 3 M\u0117nesi\u0173<\/strong> (nulinis skausmo balas)<\/td><td>7,1 %<\/td><td>37,9 %<\/td><td>533% padid\u0117jimas bendro skausmo mal\u0161inimo tikimyb\u0117s.<\/td><\/tr><tr><td><strong>Skausmo Mal\u0161inimo Trukm\u0117<\/strong><\/td><td>Mediana: 55 dienos\/7,9 savait\u0117s<\/td><td>Mediana: Ne\u012ftraukta per 24 savaites<\/td><td>Mal\u0161inimo trukm\u0117 trigub\u0117ja, ma\u017einant priklausomyb\u0119 nuo skausmo mal\u0161intoj\u0173.<\/td><\/tr><\/tbody><\/table><p style=\"text-align: left;\">Apibendrinant, konsoliduoti moksliniai \u012frodymai (<i>nuo pamatini\u0173 tyrim\u0173 su wIRA technologija iki esmini\u0173 III faz\u0117s klinikini\u0173 tyrim\u0173<\/i>) patvirtina VKH vaidmen\u012f kaip keli\u0173 poveiki\u0173 adjuvantin\u0119 terapij\u0105 onkologijoje: ji <strong>sustiprina ChT\/RT veiksmingum\u0105, aktyvuoja sistemin\u0119 imunin\u0119 sistem\u0105 (\u012fskaitant sinergij\u0105 su imunoterapija) ir dramati\u0161kai pagerina skausmo kontrol\u0119 bei GK<\/strong> v\u0117\u017eiu sergantiems pacientams.<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2b9b952 e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"2b9b952\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9003cfd elementor-widget elementor-widget-heading\" data-id=\"9003cfd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">6. Sistemin\u0117 Fiziologin\u0117 Nauda ir Terapinis Potencialas Kitose Patologijose<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0307397 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"0307397\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p>\u0160velnus, kontroliuojamas \u0161ilumos tiekimas per VKH su wIRA spinduliuote inicijuoja sud\u0117tingus termoreguliacinius atsakus, kurie suteikia pla\u010di\u0105 sistemin\u0119 naud\u0105, i\u0161ple\u010diant terapin\u012f potencial\u0105 u\u017e onkologijos rib\u0173:<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f8b16cd animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"f8b16cd\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">A. Raumen\u0173 ir Kaul\u0173 Sistemos ir Skausmo Valdymas<\/h3><p style=\"text-align: left;\">VKH yra veiksminga valdant l\u0117tinio skausmo sindromus, naudojant jos fiziologin\u012f poveik\u012f raumen\u0173 tonusui ir mikrocirkuliacijai:<\/p><ul><li style=\"text-align: left;\"><strong>Dorsalgija (L\u0117tinis Nugaros Skausmas):<\/strong> Tyrimai rodo, kad lengva VKH, derinama su stacionaria multimodaline skausmo terapija, suteikia \u017eymi\u0105 naud\u0105 pacientams, sergantiems l\u0117tiniu nespecifiniu apatin\u0117s nugaros dalies skausmu (dorsalgija) [53, 54].<\/li><li style=\"text-align: left;\"><strong>Fibromialgijos Sindromas (FMS):<\/strong> VKH yra dokumentuotas papildomas FMS gydymo b\u016bdas. Atsitiktini\u0173 im\u010di\u0173 kontroliuojami tyrimai parod\u0117 lengvos wIRA VKH veiksmingum\u0105 standartin\u0117je multimodalin\u0117je reabilitacijos aplinkoje, parodant poveik\u012f <strong>skausmo intensyvumui<\/strong> ir <strong>psichinei b\u016bsenai<\/strong> [17, 56, 57]. \u0160i nauda i\u0161 dalies susijusi su pager\u0117jusia mikrocirkuliacija, \u017einoma FMS pacient\u0173 problema [55].<\/li><li style=\"text-align: left;\"><strong>Ankilozuojantis Spondilitas (AS):<\/strong> VKH parod\u0117 imunomoduliacin\u012f poveik\u012f AS pacientams, o tyrimai prane\u0161a apie VKH geb\u0117jim\u0105 padidinti prie\u0161u\u017edegiminius mediatorius, tokius kaip <strong>Interleukinas-10<\/strong> (IL-10), ir moduliuoti pro-u\u017edegiminius citokinus, tokius kaip TNF-alfa, rodydami nauding\u0105 vaidmen\u012f valdant l\u0117tin\u012f u\u017edegim\u0105, susijus\u012f su \u0161ia b\u016bkle [58, 59, 52].<\/li><li style=\"text-align: left;\"><strong>Raynaud\u2019o Fenomenas Sergant Sistemin\u0117 Skleroze:<\/strong> Infraraudonaisiais spinduliais tarpininkaujama hipertermija buvo nustatyta kaip veiksminga gydant vazokonstrikcinius simptomus, susijusius su Scleroderma-Susijusiu Raynaud\u2019o Fenomenu, rodanti kraujagysli\u0173 naud\u0105 [49].<\/li><\/ul><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">\u00a0<\/h3><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b0c1b89 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"b0c1b89\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">B. \u0160irdies ir Kraujagysli\u0173 bei Kraujotakos Sveikata \u2764\ufe0f<\/h3><p style=\"text-align: left;\">Be naviko perfuzijos pagerinimo, VKH turi specifin\u012f poveik\u012f kraujotakos sistemai:<\/p><ul><li style=\"text-align: left;\"><strong>Esencin\u0117 Hipertenzija:<\/strong> Tyrim\u0173 serija tyr\u0117 lengvos IR-A hipertermijos naudojim\u0105 pacientams, sergantiems arterine hipertenzija (PSO I ir II stadijos). I\u0161vados rodo, kad serijinis gydymas gali teigiamai paveikti <strong>centrin\u0119 ir periferin\u0119 pulso bangas<\/strong>, kraujosp\u016bd\u012f ir <strong>kraujo klampum\u0105<\/strong>, patvirtindamas VKH vaidmen\u012f kaip nefarmakologinio fizin\u0117s terapijos galimyb\u0119 [44, 47].<\/li><\/ul><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">\u00a0<\/h3><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ce4fdb9 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"ce4fdb9\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \" style=\"text-align: left;\"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h3 style=\"text-align: left;\">C. Neuro-Endokrininis ir Psichologinis Poveikis<\/h3><p style=\"text-align: left;\">VKH \u012ftraukia organizmo neuro-endokrinines sistemas, paveikdama nuotaik\u0105 ir metabolizm\u0105:<\/p><ul><li style=\"text-align: left;\"><strong>Didelis Depresinis Sutrikimas (DDS):<\/strong> Atsitiktini\u0173 im\u010di\u0173 klinikinis tyrimas parod\u0117, kad viena VKH sesija gali veikti kaip greitai veikiantis antidepresantas, sukeliantis depresijos simptom\u0173 suma\u017e\u0117jim\u0105 kelioms savait\u0117ms. \u0160is poveikis siejamas su kar\u0161\u010dio indukuotu imunini\u0173 ir u\u017edegimini\u0173 keli\u0173 aktyvavimu, kurie veikia smegenis [51].<\/li><li style=\"text-align: left;\"><strong>Hormoninis Moduliavimas (Endokrinologija):<\/strong> VKH stimuliuoja <strong>Hipotalamo-Hipofiz\u0117s-Antinks\u010di\u0173 (HHA) a\u0161\u012f<\/strong> ir veikia hormon\u0173 lyg\u012f. Tyrimai dokumentavo <strong>Augimo Hormono<\/strong> ir <strong>Prolaktino<\/strong> atsakus viso k\u016bno hipertermijos metu, pabr\u0117\u017eiant jos poveik\u012f endokrininei reguliacijai [42, 43].<\/li><li style=\"text-align: left;\"><strong>Metabolizmas ir L\u0105steli\u0173 Reakcija:<\/strong> VKH pagreitina bazin\u012f med\u017eiag\u0173 apykaitos greit\u012f. L\u0105steli\u0173 lygmeniu kar\u0161tis veikia pO2 kinetik\u0105 ir yra susij\u0119s su apsaugini\u0173 baltym\u0173, toki\u0173 kaip <strong>feritinas<\/strong>, sinteze odoje, palaikydamas audini\u0173 atsistatym\u0105 [48; 46].<\/li><\/ul><\/header><\/header><p>\u00a0<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-91f7153 elementor-invisible elementor-widget elementor-widget-image\" data-id=\"91f7153\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/ardenneiratherm.com\/wp-content\/uploads\/2025\/10\/von-Ardenne-Iratherm-10000-WBH-wIRA-hyperthermia-device-summary.jpg\" title=\"\" alt=\"von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-summary\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ae37e3c e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"ae37e3c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a7dda12 elementor-widget elementor-widget-heading\" data-id=\"a7dda12\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Da\u017enai U\u017eduodami Klausimai (DUK) Apie Rekomenduojamas VKH Sesijas ir Tikslines Temperat\u016bras<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-aa3b4f4 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"aa3b4f4\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><i>Gydymas turi b\u016bti atliekamas tik pasitarus su gydytoju.<\/i><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header><h4>\u00a0<\/h4><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-968c093 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"968c093\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header><h4>Koks yra rekomenduojamas Viso K\u016bno Hipertermijos (VKH) protokolas esencinei hipertenzijai?<\/h4><p>Protokolas esencinei hipertenzijai rekomenduoja 12 sesij\u0173, kuri\u0173 tikslin\u0117 temperat\u016bra yra 38.3 \u00b0C. Kiekviena sesija trunka ma\u017edaug 45 minutes, apiman\u010dias 30 minu\u010di\u0173 didinimo faz\u0119 ir 15 minu\u010di\u0173 poilsio faz\u0119 (be plato faz\u0117s).<\/p><h4>Kokie yra rekomenduojami VKH parametrai l\u0117tiniam nugaros skausmui (Dorsalgijai)?<\/h4><p>Dorsalgijai paprastai rekomenduojamos 6 sesijos, kuri\u0173 tikslin\u0117 temperat\u016bra yra 38.4 \u00b0C. Bendras sesijos laikas yra ma\u017edaug 90 minu\u010di\u0173, su 45 minu\u010di\u0173 didinimu, 15 minu\u010di\u0173 plato faze ir 30 minu\u010di\u0173 poilsiu.<\/p><h4>Koks yra VKH protokolas Fibromialgijai ir Ankilozuojan\u010diam Spondilitui?<\/h4><p>Tiek Fibromialgija, tiek Ankilozuojantis Spondilitas paprastai laikosi 6 sesij\u0173 protokolo, kurio tikslin\u0117 temperat\u016bra yra 38.5 \u00b0C. Bendras sesijos laikas yra apie 90 minu\u010di\u0173, \u012fskaitant 45 minu\u010di\u0173 didinim\u0105, 15 minu\u010di\u0173 plato ir 30 minu\u010di\u0173 poils\u012f.<\/p><h4>Koks yra rekomenduojamas protokolas VKH kaip Papildomam V\u0117\u017eio Gydymui?<\/h4><p>Kaip papildomo v\u0117\u017eio gydymo protokolas reikalauja 2 ar daugiau sesij\u0173, nukreipt\u0173 \u012f bazin\u0119 temperat\u016br\u0105 nuo 39.0 \u00b0C iki 40.0 \u00b0C. Bendras sesijos laikas yra ilgiausias, svyruojantis nuo 3 iki 4 valand\u0173, kuris apima 60-90 minu\u010di\u0173 didinimo fazei, 60-90 minu\u010di\u0173 plato fazei ir 60 minu\u010di\u0173 poilsio fazei.<\/p><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><header>.<table width=\"1151\"><tbody><tr><td width=\"278\">\u00a0<\/td><\/tr><\/tbody><\/table><\/header><\/header><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3875720 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"3875720\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><div><div class=\"wpb_content_element \"><div><div><header id=\"ut_header_68e7a7d03d95c\"><header><table width=\"1151\"><tbody><tr><td width=\"278\">Indikacija<\/td><td width=\"99\">Sesij\u0173 sk.<\/td><td width=\"135\">Tikslin\u0117 temperat\u016bra<\/td><td colspan=\"2\" width=\"309\">Terapijos laikas<br \/>Didinimo faz\u0117\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Plato faz\u0117<\/td><td width=\"164\">Poilsio laikas<br \/>Poilsio faz\u0117<\/td><td width=\"164\"><b>Bendras<\/b><br \/><b>VKH sesijos laikas<\/b><\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Esencin\u0117 Hipertenzija<\/td><td rowspan=\"2\" width=\"99\">12<\/td><td rowspan=\"2\" width=\"135\">38.3 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>30 min<\/b><\/td><td rowspan=\"2\" width=\"164\">15 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 45 min<\/b><\/td><\/tr><tr><td width=\"155\">30 min<\/td><td width=\"155\">0 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Dorsalgija<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38.4 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Fibromialgija<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38.5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Ankilozuojantis Spondilitas<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38.5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Sistemin\u0117 Skleroz\u0117<\/td><td rowspan=\"2\" width=\"99\">15<\/td><td rowspan=\"2\" width=\"135\">38.3 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>30 min<\/b><\/td><td rowspan=\"2\" width=\"164\">15 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 45 min<\/b><\/td><\/tr><tr><td width=\"155\">30 min<\/td><td width=\"155\">0 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Didelis Depresinis Sutrikimas<\/td><td rowspan=\"2\" width=\"99\">1+<\/td><td rowspan=\"2\" width=\"135\">38.5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>105 -170 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 2-3 valandos<\/b><\/td><\/tr><tr><td width=\"155\">45-110 min<\/td><td width=\"155\">60 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Papildomas V\u0117\u017eio Gydymas<\/td><td rowspan=\"2\" width=\"99\">2+<\/td><td rowspan=\"2\" width=\"135\">39.0-40.0 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>120-180 min<\/b><\/td><td rowspan=\"2\" width=\"164\">60 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 3-4 valandos<\/b><\/td><\/tr><tr><td width=\"155\">60-90 min<\/td><td width=\"155\">60-90 min<\/td><\/tr><\/tbody><\/table><\/header><\/header><header id=\"ut_header_68e7a7d03d95c\"><\/header><h2>\u00a0<\/h2><\/div><\/div><\/div><\/div><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d0149af animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"d0149af\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\"><header>PASTABA: \u0160is straipsnis n\u0117ra i\u0161samus VKH wIRA tyrim\u0173 ir poveiki\u0173 s\u0105ra\u0161as<\/header><\/header><h2>\u00a0<\/h2><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0f3186c e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"0f3186c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-072e6e2 elementor-widget elementor-widget-heading\" data-id=\"072e6e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Nuorodos ir Citatos<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d13e67b animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"d13e67b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><section><ol><li style=\"text-align: left;\">Ardenne M. von. Moderate Hyperthermie als Behandlungsmethode mit vielen Indikationen. \u00c4rztzeitschr Naturheilverf 1994; 5:356-61.<\/li><li style=\"text-align: left;\">B\u00e4umler H., Scherf H.P., Aurisch R., et al. Einflu\u00df einer Serie von Infrarot-Ganzk\u00f6rperbestrahlungen auf Flie\u00dfeigenschaften des Blutes und die H\u00e4modynamik. Perfusion 1990: 138-43.<\/li><li style=\"text-align: left;\">Heckel M. Ganzk\u00f6rper-Hyperthermie und Fiebertherapie, Grundlagen und Praxis. Stuttgart: Hippokrates Verlag, 1990.<\/li><li style=\"text-align: left;\">Kosaka M., Sugahara T., Schmidt K.L., Simon E. Thermotherapy: Principles and Practice. Heidelberg: Springer Verlag, 2000.<\/li><li style=\"text-align: left;\">Meffert H., Hecht H.C., G\u00fcnther H., et al. Biophysikalische Ergebnisse des klinischen Tests der IRA-Therm-Hyperthermietechnik der 2. Generation. ThermoMed 1990; 6:71-78.<\/li><li style=\"text-align: left;\">Schmidt K.L. Hyperthermie und Fieber, Wirkungen bei Mensch und Tier. 2. \u00fcberarb Aufl. Stuttgart: Hippokrates Verlag, 1987.<\/li><li style=\"text-align: left;\">Vaupel P., Kr\u00fcger W. W\u00e4rmetherapie mit wassergefilterter Infrarot-A-Strahlung, Grundlagen und Anwendungsm\u00f6glichkeiten. 2. \u00fcberarb Aufl. Stuttgart: Hippokrates Verlag, 1995.<\/li><li style=\"text-align: left;\">Piazena H., Meffert H. Optische Eigenschaften der Haut und die photobiologischen Grundlagen zur Dosierung von IR-Hautbestrahlungen in vivo und in vitro. 6. Symposium Licht und Gesundheit 2008 13.-14.03. Berlin, 2008:162-178.<\/li><li style=\"text-align: left;\">Zschaeck S. and Beck M. Chapter 8 Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?<\/li><li style=\"text-align: left;\">Zhang H, Wang W, Zhang S, Huang W. Comparison of the anti-tumor effects of various whole-body hyperthermia protocols&#8230; Immunol Invest. 2005;34(3):245-58.<\/li><li style=\"text-align: left;\">Abreu MM, Chocron AF, Smadja DM. From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy. Front Immunol. 2025 Feb 28;16:1487296.<\/li><li style=\"text-align: left;\">Bull JMC. et al. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-\u03b1: A description of a phase I-II protocol. Journal of Hyperthermia. 2008; 24(8): 649-662.<\/li><li style=\"text-align: left;\">Weigelin B. Visualization of the immune effect of hyperthermia. ICHO 2021, Session: Hyperthermia and immunology.<\/li><li style=\"text-align: left;\">Faghihi Moghaddam F, Bakhshandeh M, Mofid B, et al. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone&#8230; J Therm Biol. 2024 Feb;120:103804.<\/li><li style=\"text-align: left;\">Hildebrandt B, Dr\u00e4ger J, Kerner T. et al. Whole-body hyperthermia in the scope of von Ardenne\u2019s systemic cancer multistep therapy (sCMT)&#8230; International Journal of Hyperthermia. 2004;3:317\u2013333.<\/li><li style=\"text-align: left;\">Atmaca A., Al-Batran S.E., Neumann A., et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer \u2013 a phase II study. Gynecol Oncol 2009; 2:384-88.<\/li><li style=\"text-align: left;\">Brockow T., Wagner A., Franke A., Offenb\u00e4cher M., Resch K.L. A Randomized Controlled Trial on the Effectiveness of Mild Water-filtered Near Infrared Whole-body Hyperthermia&#8230; Clin J Pain 2007; 1:67-75.<\/li><li style=\"text-align: left;\">Kleef R, Nagy R, Baierl A, et al. Low-dose Ipilimumab plus Nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series&#8230; Cancer Immunol Immunother. 2021;70:1393\u2013403.<\/li><li style=\"text-align: left;\">Adachi H., Katsuno M., Waza M., et al. Heat shock proteins in neurodegenerative diseases: Pathogenic roles and therapeutic implications. Int J Hyperthermia 2009; 8:647-54.<\/li><li style=\"text-align: left;\">Atmaca A., Al-Batran S.E., Neumann A., et al. Whole-body hyperthermia (WBH) in combination with carboplatin&#8230; Gynecol Oncol 2009; 2:384-88.<\/li><li style=\"text-align: left;\">Bull J.M., Scott G.L., Figueroa G., et al. An Update of a Phase II Clinical Trial Using Fever-Range Whole-Body Thermal Therapy (FR-WB-TT)&#8230; Soc for Thermal Med Joint Annual Meeting, 14.-17.5.2007.<\/li><li style=\"text-align: left;\">Bull J.M., Scott G.L., Strebel F.R., et al. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine and daily interferon-\u03b1: A description of a phase I-II protocol. Int J Hyperthermia 2008; 8:649-62.<\/li><li style=\"text-align: left;\">Bull J.M., Nagle V.L., Scott G., et al. A phase-I-study of optimally-timed Gemcitabine + Cisplatin\/Interferon-a combined with long-duration, low-temperature whole-body hyperthermia. ESHO 2001, Verona\/ Italy, 30.05.-02.06.2001:67.<\/li><li style=\"text-align: left;\">Capitano M., Mace T., Nemeth M., et al. A novel strategy for improving neutrophil recovery following total body irradiation. Soc for Thermal Med Joint Annual Meeting, 24.-26.4.2010.<\/li><li style=\"text-align: left;\">Dayanc B.E., Ostberg J.R., Repasky E.A. Enhancement of NK Cell Cytotoxic Activity by Mild Thermal Stress. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Hajto T., Hostanska K. Effect of in vivo hyperthermia on human natural killer cells. Clin Trials J 1985; 6:514-20.<\/li><li style=\"text-align: left;\">Hattori T., Kokura S., Okuda T., et al. Antitumor effect of whole body hyperthermia with \u03b1-galactosylceramide in a subcutaneous tumor model of colon cancer. Int J Hyperthermia 2007; 7:591-98.<\/li><li style=\"text-align: left;\">Kisailus A., Pritchard M., Li Y., Ostberg J., Repasky E.A. Thermal Regulation of Antigen Presenting Cells: Use of Hyperthermia as an Adjuvant for Cancer Vaccines. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Multhoff G. Letter to Editor, Hyperthermia classic commentary: Activation of natural killer (NK) cells by heat shock protein 70&#8230; Int J Hyperthermia 2009; 3:176-79.<\/li><li style=\"text-align: left;\">Peer A.J., Grimm M.J., Zynda E.R., Repasky E.A. Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunol Res 2010; 1-3:137-154.<\/li><li style=\"text-align: left;\">Rowe R.W., Stebel F.R., Proett J.M., et al. Fever-range whole body thermotherapy combined with oxaliplatin: A curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia 2010; 6:565-76.<\/li><li style=\"text-align: left;\">Schencking M., Frese T., Sandholzer H. Behandlung einer Radikulopathie bei oss\u00e4rer Metastasierung der Lendenwirbels\u00e4ule durch Infrarot-A-Ganzk\u00f6rperhyperthermie. Forsch Komplementmed 2008; 15:273-76.<\/li><li style=\"text-align: left;\">Scott G.L., Bull J.M.C., Kochn M. Management of Conscious Sedation&#8230; 9th Int Congress on Hyperthermic Oncology, 20.-24.4.2004.<\/li><li style=\"text-align: left;\">Shecterle L.M., Cyr J.A.S. Hyperthermia Aids Patients with Advanced Lung Cancer. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Skitzki J.J., Repasky E.A., Evans S.S. Hyperthermia as an immunotherapy strategy for cancer. Current Opnion in Investigational Drugs 2009; 6: 550-58.<\/li><li style=\"text-align: left;\">Toyota N., Strebel F.R., Stephens L.C., et al. Long-duration, mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis&#8230; Int. J. Hyperthermia 1997; 5:497-506.<\/li><li style=\"text-align: left;\">Wang X.Y., Kazim L., Repasky E.A., Subjeck J.R. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines&#8230; J of Immunology 2001; 165:490-97.<\/li><li style=\"text-align: left;\">VanderZee J., DeBruijne M., Mens J.W.M., et al. Reirradiation combined with hyperthermia in breast cancer recurrences&#8230; Int J Hyperthermia 2010; 7:638-48.<\/li><li style=\"text-align: left;\">Zagar T.M., Oleson J.R., Vujaskovic Z., et al. Hyperthermia for locally advanced breast cancer. Int J Hyperthermia 2010; 7:618-24.<\/li><li style=\"text-align: left;\">Zagar T.M., Oleson J.R., Vujaskovic Z., et al. Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence&#8230; Int J Hyperthermia 2010; 7: 612\u201317.<\/li><li style=\"text-align: left;\">Sen A., Capitano M., Dommer M., et al. Thermoregulatory responses to mild systemic thermal stress increase tumor perfusion&#8230; Cancer Res. 2011; 71(11):3872-3880.<\/li><li style=\"text-align: left;\">Koska J., Rovensky J., Zimanova T., Vigas M. Growth hormone and prolactin responses during partial and whole body warm-water immersions. Acta Physiol Scand. 2003 May;178(1):19-23.<\/li><li style=\"text-align: left;\">Vigas M., Rovensky J., Zimanova T., Koska J. Responses of growth hormone and prolactin to local and whole-body application of Piestany mud. Acta Rheumatol et Balneol Pistiniana 2002:31-38.<\/li><li style=\"text-align: left;\">Meffert B., Hochmuth O., Steiner M. Effects of a multiple mild infrared a induced hyperthermia on central and peripheral pulse waves in hypertensive patients. North Sea Conference on Biomedical Engineering 1990.<\/li><li style=\"text-align: left;\">Meffert H., Scherf HP., Meffert B. Milde Infrarot-A-Hyperthermie. Auswirkungen von Serienbestrahlungen mit wassergefilterter Infrarotstrahlung&#8230; Akt Dermatol 1993; 19:142-48.<\/li><li style=\"text-align: left;\">Applegate L.A., Scaletta C., Panizzon R., et al. Induction of the putative protein ferritin by infrared radiation: Implications in skin repair. Int J of Molecular Med 2000; 5:247-51.<\/li><li style=\"text-align: left;\">Scherf H.P., Meffert H., B\u00e4umler H., et al. Wirkung einer einmaligen milden Infrarot-A-Hyperthermie auf K\u00f6rpertemperatur, Herzfrequenz, Blutdruck und Blutviskosit\u00e4t&#8230; Dermatol Monatsschr 1989; 175:733-40.<\/li><li style=\"text-align: left;\">Streffer C. Metabolic changes during and after hyperthermia. Int J Hyperthermia 1985; 4:305-319.<\/li><li style=\"text-align: left;\">F\u00f6rster J., Fleischanderl S., Wittstock S., et al. Infrared-Mediated Hyperthermia is Effective in the Treatment of Scleroderma-Associated Raynaud\u2019s Phenomenon. J of Investigative Dermatology 2005; 6:1313-16.<\/li><li style=\"text-align: left;\">Koska J., Rovensky J., Zimanova T., et al. Sympathoadrenal regulation of circulatory responses to whole-body hyperthermia&#8230; Acta Rheumatol et Balneol Pistiniana 2002:23-30.<\/li><li style=\"text-align: left;\">Janssen C.W., Lowry C.A., Mehl M.R., et al. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder \u2013 A Randomized Clinical Trial. JAMA Psychiatry. 2016 May 12.<\/li><li style=\"text-align: left;\">Tarner I.H., Ladner U.M., Uhlemann C., Lange U. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1 beta and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 2009; 4:397-402.<\/li><li style=\"text-align: left;\">Ettrich U., Konrad B., Prate K., et al. Milde Ganzk\u00f6rperhyperthermie in Kombination mit station\u00e4rer multimodal orientierter Schmerztherapie&#8230; Orthop\u00e4de 2014; 2:165-74.<\/li><li style=\"text-align: left;\">Weller E., Ullrich D. Infrarot-A-Hyperthermie-Anwendung bei Patienten mit Analgetica-Abusus wegen chronischer R\u00fcckenschmerzen. Vortrag auf dem 95. Kongre\u00df der Gesellschaft f\u00fcr Phys Med und Rehab 5.10.1990.<\/li><li style=\"text-align: left;\">Morf S., Vesti B.A., Forster A., et al. Microcirculation abnormalities in patients with fibromyalgia \u2013 measured by capillary and laser fluxmetry. Arthritis Res Ther 2005; 7:R209-16.<\/li><li style=\"text-align: left;\">Walz J., Hinzmann J., Haase I., Witte T. Ganzk\u00f6rperhyperthermie in der Schmerztherapie \u2013 eine kontrollierte Studie an Patienten mit Fibromyalgiesyndrom. Schmerz 2013; 27:38-45.<\/li><li style=\"text-align: left;\">Romeyke T., Stummer H. Multi-modal pain therapy of fibromyalgia syndrome with integration of systemic whole-body hyperthermia&#8230; J Musculoskel Pain 2014; 4:341-55.<\/li><li style=\"text-align: left;\">Zauner D., Quehenberger F., Hermann J., et al. Whole body hyperthermia treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis: A pilot study. Int J Hyperthermia 2014; 6:393-401.<\/li><li style=\"text-align: left;\">Lange U., M\u00fcller-Ladner U., Dischereit G. Wirkung iterativer Ganzk\u00f6rperhyperthermie mit wassergefilterter Infrarot-A-Strahlung bei ankylosierender Spondylitis&#8230; Akt Rheumatol 2017; 2:122-128.<\/li><\/ol><\/section><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-97dc368 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"97dc368\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><section><p>\u00a0<\/p><\/section><footer>\u00a9 <time>2025<\/time> Romanian Society Oncologic Hyperthermia All rights reserved. Source: Analysis based on scientific literature.<\/footer><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Viso K\u016bno Hipertermija (VKH \/ WBH) Onkologijoje ir Kitose Patologijose: Konsoliduota Sinergija, Imunomoduliacija ir Klinikiniai \u012erodymai Paskelbta: 2025-10-13 | Paskutin\u012f Kart\u0105 Per\u017ei\u016br\u0117ta: 2025-10-13 Autoriai Veronica Iatan, MD, Cristian Gologan, M.Sc. Viso K\u016bno Hipertermija (VKH \/ WBH) yra sistemin\u0117 onkologin\u0117 strategija, apimanti kontroliuojam\u0105 k\u016bno bazin\u0117s temperat\u016bros k\u0117lim\u0105, da\u017enai naudojant vandeniu filtruoto Infraraudonojo-A (wIRA) technologij\u0105. VKH i\u0161<br \/><a class=\"moretag\" href=\"https:\/\/ardenneiratherm.com\/lt\/klinikiniai-tyrimai-hipertermija-onkologija\/\">+ Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/page-fullwidth_template.php","meta":{"footnotes":""},"class_list":["post-982","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ardenneiratherm.com\/lt\/wp-json\/wp\/v2\/pages\/982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ardenneiratherm.com\/lt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ardenneiratherm.com\/lt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ardenneiratherm.com\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ardenneiratherm.com\/lt\/wp-json\/wp\/v2\/comments?post=982"}],"version-history":[{"count":0,"href":"https:\/\/ardenneiratherm.com\/lt\/wp-json\/wp\/v2\/pages\/982\/revisions"}],"wp:attachment":[{"href":"https:\/\/ardenneiratherm.com\/lt\/wp-json\/wp\/v2\/media?parent=982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}